Performance Evaluation of Dry Chemical Colorimetry for Plasma Ammonia Detection on the VITROS 350 Chemistry System Authors: Jia Liu, Lin Wang, Yue Tang, Peiran Li, Lili Zhao, Wenwen Yuan, Bo Li, Boan Li Published: 2026 ABSTRACT ABSTRACTObjectivePlasma ammonia quantitation is one of the most valuable laboratory tests for assessing hepatic function. Accurate measurement is clinically imperative for the diagnosis and management of severe hepatobiliary diseases. This study aimed to comprehensively evaluate the analytical performance of the VITROS dry chemistry system with dry chemical colorimetry for plasma ammonia detection.MethodsA full performance validation was conducted on the VITROS 350 Chemistry System in accordance with the guidelines of the Clinical and Laboratory Standards Institute (CLSI) and the China National Accreditation Service for Conformity Assessment (CNAS). Comparability was performed using the VITROS 350 Chemistry System and VITROS 5600 Integrated System across our center and four external laboratories.ResultsThe VITROS 350 platform demonstrated robust analytical performance for plasma ammonia testing. Precision, accuracy, upper limit of the reportable interval, linearity, and carryover rates were all compliant with both clinical requirements and manufacturer specifications. Comparative analysis revealed strong inter‐platform concordance, with results from five concentration levels across five laboratories remaining within predefined allowable limits. Regarding interference, only high concentrations of hemoglobin exerted a clinically significant impact on test results, a finding consistent with established clinical experience and diagnostic expectations.ConclusionThis study validates the reliability of the VITROS dry chemistry system for routine plasma ammonia testing. It provides clinical laboratories with a robust framework for method selection and establishes a framework for future external quality assessment (EQA) based on dry chemistry colorimetry. Introduction Ammonia is an endogenous metabolic product that plays an essential role in maintaining acid‐base homeostasis and regulating protein metabolism in the human body [1]. Under physiological conditions, ammonia produced in peripheral tissues is transported to the liver via the portal circulation and efficiently detoxified through the urea (ornithine) cycle, after which it is excreted by the kidneys [2]. However, in the presence of severe hepatic dysfunction—such as liver cirrhosis or acute liver failure—the liver's capacity for ammonia clearance is markedly impaired, resulting in elevated plasma ammonia levels and the development of hyperammonemia [3]. Hyperammonemia may lead to hepatic encephalopathy, a potentially life‐threatening complication of liver disease [4]. Epidemiological studies indicate that approximately 30%–40% of patients with cirrhosis develop hepatic encephalopathy during their illness. Moreover, even mild or subclinical hyperammonemia has been shown to impair cognitive function and worsen neurological outcomes in cirrhotic patients [5, 6]. Recent evidence indicates that plasma ammonia concentrations can predict hospitalization due to liver‐related complications and mortality in clinically stable outpatients with cirrhosis [7, 8]. Mechanistically, ammonia accumulation induces cellular stress responses that contribute to astrocyte swelling, oxidative stress, and neuroinflammation, thereby promoting the development and progression of hepatic encephalopathy [9]. According to the European Association for the Study of the Liver (EASL) Clinical Practice Guidelines, accurate ammonia measurement is essential for diagnosis, severity assessment, and therapeutic monitoring in patients with liver disease [10]. In addition, timely ammonia detection is critical in the diagnosis and management of urea cycle disorders, where delayed or inaccurate measurement may be fatal [11]. At present, various analytical methods are available for plasma ammonia determination, including the ion‐selective electrode method, glutamate dehydrogenase (GLDH) enzymatic assay, colorimetric method, and microdiffusion method [12, 13]. The GLDH enzymatic method has become the mainstream technique in many clinical laboratories due to its widespread adoption of fully automated biochemical analyzers. Nevertheless, enzymatic assays may be affected by the presence of lipemia, bilirubinemia, or vitamin K1 medication [14, 15, 16]. In contrast, the dry chemistry colorimetric method eliminates the need for complex liquid‐handling modules, reagent dispensing systems, and extensive fluidic pipelines that characterize conventional wet‐chemistry platforms. Using a semipermeable membrane that excludes aqueous components, the dry chemistry approach allows specific chemicals to diffuse through multiple layers while minimizing the risk of interference at the source [17, 18]. Owing to its unique workflow, improved reaction efficiency, and enhanced interference resistance, the dry chemistry method would be a core technology for plasma ammonia measurement. Despite advances in analytical techniques, plasma ammonia testing remains insufficiently standardized. Currently, no universally accepted gold standard method exists, leading to considerable interlaboratory variability in testing procedures, reagent formulations, and quality control systems. These inconsistencies limit result comparability and may compromise the clinical interpretation of ammonia measurements. Considering that the measurement of plasma ammonia is highly sensitive to preanalytical conditions, including sample handling, transportation, storage time, and temperature [15, 19], there are limited studies evaluating the comparability of plasma ammonia levels measured using different analytical platforms or across various laboratories [20]. Therefore, establishing and validating robust analytical procedures for plasma ammonia measurement is of critical importance to ensure reliable clinical decision‐making. Accordingly, the aim of this study was to comprehensively evaluate, for the first time, the analytical performance of plasma ammonia detection using the VITROS 350 Chemistry System, in accordance with guidelines from the Clinical and Laboratory Standards Institute (CLSI) and the China National Accreditation Service for Conformity Assessment (CNAS). Performance verification encompassed assessments of precision, accuracy, upper limit of the reportable interval, linearity, comparability, interference, and carryover. Materials and Methods Samples The study population consisted of blood samples obtained from 30 adult hospitalized patients and 30 individuals undergoing health examinations at the Department of Clinical Laboratory of the Fifth Medical Center of the Chinese People's Liberation Army General Hospital. Venous blood (3 mL) was collected into lithium‐heparin tubes and immediately transported to the laboratory in an ice box, ensuring arrival within 15 min and then separated by centrifugation (1500 × g for 10 min at 4°C). Critically, all samples exhibiting hemolysis, icterus, or lipemia via visual inspection were excluded. Plasma samples were retrospectively collected from individuals who had not received vitamin K1 medication. Additionally, the same 60 plasma samples spanning a broad concentration range were used for further validation testing. The demographic characteristics of these participants are summarized in Table S1. The study protocol was approved by the Institutional Ethics Committee (KY‐2024‐10‐172‐2), and all participants provided written informed consent prior to specimen collection. Analyzer, Reagents, and Other Materials Plasma ammonia measurements were analyzed on the VITROS 350 fully automated chemical analyzer (QuidelOrtho, CA, US) in our laboratory, using the corresponding ammonia test dry slides (Lot. #101902644147) and calibrator (Lot. #0543). To evaluate analytical precision, two levels of VITROS LV quality control (Lot. #D1516, E1517) obtained from QuidelOrtho and additional levels of Bio‐Rad quality control materials (Lot. #54421, 54,422, 54,423; Bio‐Rad Laboratories, CA, US) were used throughout the study. For cross‐platform comparability assessment, QC materials and dry slides from the same lot numbers were distributed via air express to four external laboratories with a VITROS 350 Dry Chemistry System or VITROS 5600 Integrated System (QuidelOrtho). Interference testing was conducted using Interference Check A Plus kits (Lot# ZR2501, Sysmex, Kobe, Japan) and vitamin K1 injection (Lot. #11250422, Zhejiang Chengyi Pharmaceutical Co. Ltd., Shanghai, China). Precision Verification Precision was evaluated in accordance with CLSI EP15‐A3 [21]. Testing was performed using five QC levels, with one run per day over five consecutive days. Each run comprised five replicates, yielding 25 measurements per level. The repeatability standard deviation (SR), coefficient of variation (CV), and within‐laboratory imprecision standard deviation (SWL) were calculated. Manufacturer‐stated performance specifications indicate within‐laboratory CVs of 8.5% for VITROS PV Level 1% and 3.2% for VITROS PV Level 2 [22]. The acceptance criterion was defined as CV ≤ 1/3 of the inter‐laboratory quality assessment criterion, corresponding to a CV < 10%, which was established by the Shanghai Center for Clinical Laboratory. Accuracy Verification Accuracy testing was conducted in accordance with CNAS‐GL037 [23]. Ten consecutive measurements were performed on calibrated materials provided by the manufacturer within the same reagent lot. The bias was calculated based on the mean value derived from these repeated measurements and evaluated against the ammonia performance criteria established by the Royal College of Pathologists of Australasia quality assurance program (RCPA QAP) [24]. The allowable bias was defined as ±5 μmol/L and ±10%, when ammonia concentration ≤ 50 μmol/L or > 50 μmol/L, respectively. Validation of the Upper Limit of the Reportable Interval Plasma ammonia assay on the VITROS 350 specifies the limit of quantification (LOQ) of 8.7 μmol/L and an upper limit of quantification (ULoQ) of 500 μmol/L [22]. Following the CLSI EP34 protocol [25], three high‐concentration samples (75%–100% of ULoQ) were diluted with reagent‐grade water at a 1:2 ratio (sample: diluent). Both undiluted and diluted samples were analyzed in triplicate, and the average dilution recovery rate (DRC) was calculated as follows: DRC=Meandiluted sample×Dilution factorMeanundiluted sample×100% A DRC of 90%–110% (maximum deviation ≤ ±10%) was considered acceptable. According to CLSI EP34, the extended measurement interval (EMI) encompasses analyte concentrations measurable with acceptable accuracy post‐dilution. The upper limit of the EMI was derived by multiplying the ULoQ by the dilution factor, thus defining the upper bound of the reportable interval. Linearity Verification The linearity test was verified according to CLSI EP06‐2nd [26]. High‐(H) and low‐(L) plasma ammonia concentration patient samples, confirmed to be free of interfering substances, were selected to bracket the analytical range. The high‐concentration sample was prepared near the upper limit of quantification (ULoQ > 450 μmol/L), and the low‐concentration sample was prepared near the lower limit (LLoQ < 20 μmol/L). Six concentration gradients were generated via serial dilution, as detailed in Table S2. Each gradient was tested in triplicate, and the mean values were used for analysis. Weighted least squares regression was performed, with expected concentrations as the x‐axis and measured means as the y‐axis, and the result were presented as the linear equation Y = aX + b and the correlation coefficient (R 2). Linearity was considered acceptable across the entire range at each concentration level if the 95% confidence interval (CI) overlapped with ±the allowable deviation from linearity (ADL). The ADL was set at 1/2 the total allowable error (TEa) in line with RCPA QAP requirements (Table S3). Comparability Verification Currently, China lacks a national external quality assessment (EQA) program for plasma ammonia testing, and the instability of samples further complicates proficiency testing. To address this, an alternative interlaboratory comparability was implemented by CNAS‐GL047 [27]. Five plasma ammonia control materials with different concentrations—comprising two levels of VITROS Liquid PV controls and three Bio‐Rad controls—were distributed to five participating laboratories (labeled A–E). The analyses were performed using either the VITROS 350 or VITROS 5600 analyzer. Each laboratory carried out three replicate measurements for each control level using the same reagent batch. The mean value from each laboratory for each control level was calculated, and the median of these means across all laboratories was established as the target value. The permissible error range was defined as the median ± allowable deviation, based on criteria from RCPA QAP with 1/2 the TEa. A laboratory was deemed qualified if at least four out of the five tested samples fell within the predefined permissible range. Interference Interference testing was carried out in accordance with CLSI EP07‐A3 [28]. Baseline ammonia concentrations were maintained at 12–30 μmol/L for the low‐pool and 55–85 μmol/L for the high‐pool. Four common endogenous interferents—hemoglobin (indicating hemolysis), unconjugated and conjugated bilirubin (indicating jaundice), and triglycerides (indicating lipemia)—were prepared following the manufacturer's instructions. A 10 mg/mL vitamin K1 injection was diluted with distilled water at a ratio of 1:119 to yield an 83 μg/mL interferent stock solution. The interference sample was prepared by adding a known concentration of the interferent to the baseline sample, whereas the control received an equal volume of blank solution. The final interferent concentrations corresponded to the highest levels tested. All samples were analyzed within a single analytical run to minimize between‐run variability, with five replicates performed for each sample. The mean ammonia concentration was calculated for each group. The interference effect was quantified as follows: Absolute deviation=Xtest−Xcontrol Relative deviation%=Absolute deviationXcontrol×100% The results were subsequently evaluated against the allowable bias limits defined by the RCPA QAP. Carryover Effect Carryover was evaluated using two high‐concentration samples (H1, H2) positioned near the upper limit of quantification (ULoQ) and one low‐concentration sample (L) prepared just above the lower limit of quantification (LLoQ). The L sample was aliquoted into three equal portions (L1, L2, L3). Testing was performed in the sequence H1–H2–L1–L2–L3, with this cycle repeated four times per run, and a total of five independent runs were completed. The carryover rate was calculated as follows: Carryover rate%=L1−L3L3×100 The acceptance criterion was defined as a carryover rate ≤ 2 × the standard deviation (SD) of the low‐concentration sample, in accordance with the practical guide described by Joachim Pum [29]. Statistical Analysis All statistical analyses were performed using SPSS software (version 23.0; IBM Corp., NY, US). Figures were generated by GraphPad Prism (version 10.1.2; GraphPad Software, CA, US). Results Precision Results The precision of the VITROS 350 system was evaluated across five ammonia QC concentration levels, assessing both repeatability and within‐laboratory imprecision. As detailed in Table 1, the repeatability standard deviation (SR) ranged from 1.78 to 5.07 μmol/L, and the within‐laboratory standard deviation (SWL) ranged from 2.11 to 6.75 μmol/L. Correspondingly, the repeatability CV ranged from 1.70% to 6.01%, and the within‐laboratory CV ranged from 1.68% to 9.39%. In addition, the within‐laboratory CV for VITROS PV Level 1 and Level 2 was lower than the manufacturer‐stated specifications. All calculated CVs were well within the predefined acceptance criteria, confirming that the precision verification was successfully met. TABLE 1Precision results of plasma ammonia in five levels.QCMean (μmol/L)SR (μmol/L)SWL (μmol/L)Repeatability CV (%)Within laboratory CV (%)VITROS PV Level 145.121.782.113.944.68VITROS PV Level 2202.903.453.411.701.68Bio‐Rad Level 133.292.003.136.019.39Bio‐Rad Level 299.483.823.963.843.98Bio‐Rad Level 3246.435.076.752.062.74Abbreviations: CV, coefficient of variation; QC, quality control; SR, repeatability standard deviation; SWL, within‐laboratory imprecision standard deviation. Precision results of plasma ammonia in five levels. Abbreviations: CV, coefficient of variation; QC, quality control; SR, repeatability standard deviation; SWL, within‐laboratory imprecision standard deviation. Accuracy Results The accuracy of the plasma ammonia assay was evaluated using manufacturer‐provided matched calibrators with certified target values. In accordance with the CNAS‐GL037 guidelines, the calculated bias was less than the allowable total error specified by the RCPA QAP (Table 2). This verification confirms that the analytical system meets the required standards, thereby ensuring the reliable quantification of plasma ammonia in clinical patient samples. TABLE 2Accuracy validation results.CalibratorMean (μmol/L)Target value (μmol/L)Allowable biasCalculated biasLevel 112.949.30±5.00 μmol/L3.64 μmol/LLevel 295.8588.90±10%7.82%Level 3466.36455.10±10%2.47% Note: The allowable bias for this study was based on RCPA QAP. Accuracy validation results. Note: The allowable bias for this study was based on RCPA QAP. Upper Limit of the Reportable Interval Validation Results The validation of the plasma ammonia assay's upper limit of the reportable interval showed that both individual sample recovery rates and overall recovery rates were within the acceptable range of 90%–110%. Using the manufacturer‐recommended maximum dilution ratio (1:2), the overall recovery rate satisfied the required criteria, and the validation was successfully passed (Table 3). The upper limit of the reportable interval was calculated as the product of the ULoQ and the dilution factor (×2), yielding a value of 1000 μmol/L. TABLE 3Upper limit of the reportable interval validation results.SampleBefore dilution (μmol/L)After dilution (μmol/L)Dilution recovery rate (%)Overall dilution recovery rate (%)1460.33215.9093.8097.092469.20220.4793.983449.90232.83103.50 Upper limit of the reportable interval validation results. Linearity Interval Validation The linearity interval validation for the plasma ammonia test on the VITROS 350 system was summarized in Table 4. Weighted linear regression analysis yielded the equation Y = 0.998X − 0.163 and the curve is shown in Figure 1A. The linear regression analysis of the VITROS 350 system showed a line with a good correlation coefficient (R 2 = 0.999). The 95% confidence interval deviations of linearity (DL) across the concentration levels were all within the average deviation from linearity (ADL) range, confirming that linearity across the entire measurement interval was acceptable (Figure 1B). The validation was successfully passed. TABLE 4Linear test results of VITROS 350 plasma ammonia index.SampleMean (μmol/L)SD (μmol/L)Sigma valueWeightPredicted value (μmol/L)Linear deviation (μmol/L)Lower limit of the CI (μmol/L)Upper limit of the CI (μmol/L)ADL (μmol/L)114.101.151.150.7514.100.20−1.391.78±2.502105.772.431.690.35106.73−0.55−2.881.78±5.323198.474.443.180.10199.35−0.26−4.634.11±9.944292.404.314.680.05291.981.26−5.177.70±14.565383.177.566.140.03384.61−0.38−8.818.05±19.186477.236.017.640.02477.231.28−9.2211.78±23.80Abbreviations: ADL, allowable deviation from linearity; CI, confidence interval; SD, standard deviation. Linear test results of VITROS 350 plasma ammonia index. Abbreviations: ADL, allowable deviation from linearity; CI, confidence interval; SD, standard deviation. Linearity interval validation results. (A) Weighted least squares regression analysis with the fitting curve Y = 0.998X−0.163. x‐axis is the expected value and y‐axis is the measured value. The coefficient of determination (R 2) = 0.999. (B) Comparison of the 95% CI and ± ADL of linear deviation of plasma ammonia determination on the VITROS 350 system. The orange line shows the ±ADL, and the black dots display the deviations of linearity. Red and blue line represent the upper and lower limit CI, separately. The linearity is verified since all linearity deviations have a CI that intersects with the ADL. Comparability Verification The verification was designed to assess interlaboratory comparability across different VITROS platforms using stable commercial QC materials, due to the instability of plasma ammonia during transport. Testing systems in laboratories A (our laboratory), B, and C used the VITROS 350 system, whereas laboratories D and E used VITROS 5600 platform. All results across five concentration levels and five laboratories fell within the allowable deviation limits (Table 5). These findings demonstrate that the VITROS plasma ammonia assay maintains excellent comparability across different instrument models and sites. TABLE 5Results of comparability verification.QCMedian (μmol/L)Lower limit of permissible range (μmol/L)Upper limit of permissible range (μmol/L)Laboratories with values within permissible rangeVITROS liquid PV Level 145.640.650.6100%VITROS liquid PV Level 2197.7178.0217.5100%Bio‐Rad Level 132.227.237.2100%Bio‐Rad Level 295.886.3105.4100%Bio‐Rad Level 3237.4213.7261.14100% Results of comparability verification. Analytical Interferences Interference experiments were conducted to assess the bias in plasma ammonia measurements induced by hemoglobin, bilirubin, triglycerides, and vitamin K1. Figure S1 shows the impact of different interfering substances on plasma ammonia concentrations, which were added with different interferences with the results compared against the RCPA QAP allowable bias limits. Consistent with the manufacturer's instruction, which advise against testing hemolyzed samples [22]. Our study confirmed that high concentrations of hemoglobin induced positive interference at both low (L) and high (H) plasma ammonia concentrations, with the magnitude of interference increasing proportionally with hemoglobin concentration. Specifically, a hemoglobin concentration of ≥ 375 mg/dL caused the bias in low‐level samples to exceed the allowable limit, while ≥ 500 mg/dL resulted in unacceptable bias in high‐level samples (Table 6). TABLE 6Interference assessments for common interferents.InterferentLow ammonia sampleHigh ammonia sampleMean value (μmol/L)Absolute bias (μmol/L)Mean value (μmol/L)Relative bias (%)Hemoglobin (mg/dL)011.04075.900125.0012.701.6677.722.40250.0015.684.6481.046.77375.0019.488.4481.287.09500.0020.389.3484.6011.46Unconjugated bilirubin (mg/dL)012.90079.9205.0014.521.6279.68−0.3010.0012.88−0.0279.50−0.5315.0012.76−0.1478.24−2.1020.0015.182.2879.84−0.10Conjugated bilirubin (mg/dL)011.10078.2805.0012.241.1478.620.4310.0016.004.9077.18−1.4115.0014.243.1481.063.5520.0014.623.5280.923.37Triglyceride (FTU)07.74075.820450.0010.202.4677.161.77900.0012.144.4079.324.621350.009.661.9279.164.411800.0011.103.3678.483.51 Note: Absolute bias > ±5 μmol/L or relative bias > ±10% were considered unacceptable according to RCPA QAP. Interference assessments for common interferents. Note: Absolute bias > ±5 μmol/L or relative bias > ±10% were considered unacceptable according to RCPA QAP. In contrast, the assay exhibited robust resistance to other common interferents. No significant interference was observed for unconjugated bilirubin (up to 20 mg/dL) or conjugated bilirubin (Table 6). Similarly, triglycerides (up to 1800 FTU) did not significantly impact results in either group (Table 6). Regarding vitamin K1, concentrations up to 8.3 μg/mL were non‐interfering, with all biases remaining within acceptable limits (Table S4). These findings confirm that the dry chemistry colorimetric method possesses excellent interference resistance, ensuring reliable plasma ammonia quantification in complex clinical matrices. Carry‐Over Effect According to the verification protocol, the plasma ammonia assay on the VITROS 350 system was 2.3 μmol/L, corresponding to a carryover rate of 11.5% (Table 7). This result was well below the defined threshold of twice the SD (4.73 μmol/L) of the low‐concentration sample; the carryover effect was considered acceptable. TABLE 7Results of the carry‐over rate effect.Sample x¯(μmol/L)SD (μmol/L)Carry‐over (μmol/L)Carry‐over rate (%)H1454.82.282.311.5H2458.33.72L122.40.79L219.81.49L320.12.37 Note: SD represents the standard deviation. Results of the carry‐over rate effect. Note: SD represents the standard deviation. Discussion Plasma ammonia serves as a pivotal biomarker with significant diagnostic and prognostic implications across diverse clinical settings. Consequently, the accurate and timely quantification of plasma ammonia is of paramount clinical importance. This study provides a comprehensive analytical evaluation of the VITROS 350 Chemistry System for plasma ammonia measurement. The assessment encompassed critical performance metrics, including precision, accuracy, upper limit of the reportable interval, linearity, comparability, interference, and carryover. The results demonstrate that all evaluated parameters complied with both the manufacturer's specifications and the rigorous performance criteria outlined by the Clinical and Laboratory Standards Institute (CLSI) and the China National Accreditation Service (CNAS). Notably, among the various interfering substances tested, only high concentrations of hemoglobin were found to exert a significant interfering effect on plasma ammonia quantification. Precision is a fundamental aspect of analytical reliability. In this study, the VITROS 350 system demonstrated excellent precision across five levels of quality control materials from two manufacturers, with both repeatability and within‐laboratory CVs meeting the acceptance criteria. Accuracy verification, conducted using calibration materials from different production lots, revealed biases within allowable limits at all three concentration levels, confirming satisfactory trueness. The upper limit of the reportable interval was verified via dilution, yielding an overall recovery of 97.09%. This successfully validated the manufacturer‐recommended dilution protocol and extended the measurable range up to 1000 μmol/L. Linearity assessment, performed in strict accordance with CLSI EP06‐Ed2, utilized weighted least‐squares regression to model the relationship between predicted and measured values, thereby minimizing the undue influence of high‐concentration samples. The 95% confidence intervals for linear deviations remained within the allowable deviation limits (±ADL), confirming robust linearity suitable for clinical demands. In addition, comparability demonstrated strong inter‐platform agreement across all concentration levels, meeting predefined acceptance criteria and underscoring the reliability of the VITROS dry chemistry system for plasma ammonia quantification. In this study, the VITROS 350 dry chemistry system incorporates a multilayer‐coated polymer membrane, which demonstrated robust resistance to interference from hyperbilirubinemia and lipemia. We also evaluated the potential interference of vitamin K1, which has previously been reported to affect GLDH‐based ammonia assays [16]. Our results showed no significant interference at either low or high plasma ammonia concentrations. Conversely, hemolysis proved to be a substantial confounder in our analysis. Hemoglobin concentrations ≥ 375 mg/dL led to induce positive interference in measured ammonia at low concentrations, whereas levels ≥ 500 mg/dL caused falsely elevated results at higher concentrations. This observation aligns with biological expectations: intracellular ammonia concentrations are approximately 2.8‐fold higher than extracellular levels, and delayed processing or hemolysis can release intracellular ammonia via ongoing cellular metabolism. Furthermore, post‐collection, enzymes such as γ‐glutamyl transferase and transaminases can catalyze the hydrolysis of peptides and glutamine, further elevating ammonia levels [12, 30]. These findings highlight hemolysis as the primary preanalytical risk factor compromising analytical accuracy. Consequently, stringent control over sample collection, handling, and storage is imperative [31]. In our institution, grossly hemolyzed samples are not automatically rejected. If severe hemolysis is observed, the result is reported but accompanied by a mandatory comment: Gross hemolysis detected; plasma ammonia result may be affected by interference. Please interpret with caution or request recollection if clinically indicated. Beyond the analytical performance, the dry chemistry platform offers practical advantages, including minimal sample volume requirements, reduced cross‐contamination risk, and expedited turnaround times. Nevertheless, several limitations of the present study should be noted. First, this investigation did not evaluate potential interference from additional confounding substances, such as medications, lipid emulsions, or severe dysproteinemia. Second, interlaboratory variability and operator‐dependent differences in sample handling procedures were not assessed. Third, sample stability under varying transportation conditions, anticoagulants, or appropriate storage conditions and durations was not examined. These unaccounted factors may undermine the reliability of ammonia assays, representing a challenge in preanalytical correction. Thus, well‐designed multicenter studies are warranted to further validate the system's performance across a broader spectrum of clinical scenarios and operational settings. Our study verified the analytical performance of a dry chemistry colorimetric plasma ammonia assay, which fills a notable gap in the existing literature. The strong precision, accuracy, and robustness demonstrated by the VITROS 350 system in this study substantiate its suitability for clinically demanding settings, where reliable ammonia quantification is essential to informed clinical decision‐making and optimal patient care. Author Contributions Boan Li was responsible for study supervision and funding acquisition. Jia Liu, Lin Wang, Yue Tang, and Peiran Li conceptualized and designed the study, analyzed the data, and wrote the manuscript. Lili Zhao and Wenwen Yuan provided clinical samples. Bo Li provided technical support and revised the manuscript. All authors reviewed and approved the final manuscript. Funding This work was supported by Capital's Funds for Health Improvement and Research (SF2024‐1‐2171) and China International Exchange and Promotive Association for Medical and Health Care (CSK52802202501). The founders had no role in study design, data collection, or analysis. Ethics Statement Ethical documents were approved by the ethics committee of the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army (KY2024‐10‐172‐2). Written informed consent in this study was obtained from the participants. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Demographic characteristics of the study population. Table S2: Sample preparation for linearity‐interval validation. Table S3: Plasma ammonia performance criteria derived from the RCPA QAP. Table S4: Interference assessments for vitamin K1. Figure S1: Effect of interference on plasma ammonia detection. (A) Hemoglobin (indicating hemolysis). Red dots showed with absolute deviation or relative deviation were unacceptable. (B) Unconjugated bilirubin (indicating jaundice). (C) Conjugated bilirubin (indicating jaundice). (D)Triglycerides (indicating lipemia). (E) Vitamin K1. The left panel corresponds to the low concentration samples, the right panel to the assumed high concentration samples. The acceptable criteria are set according to RCPA QAP with absolute bias < ±5 μmol/L and relative bias < ±10% for plasma ammonia concentration ≤ 50 μmol/L or > 50 μmol/L, respectively.